RIGI and neoplasm: This has potential significant implications to tumor biology and suggests that RIG-I agonist-based therapies may be a potential avenue to improve responses to DNA-damaging therapies (i.e., ionizing radiation or other systemic therapies) and deserves further study both pre-clinically and clinically.